Share This Page
Drug Price Trends for NDC 00074-6624
✉ Email this page to a colleague
Average Pharmacy Cost for 00074-6624
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SYNTHROID 100 MCG TABLET | 00074-6624-11 | 1.58468 | EACH | 2025-12-17 |
| SYNTHROID 100 MCG TABLET | 00074-6624-90 | 1.58468 | EACH | 2025-12-17 |
| SYNTHROID 100 MCG TABLET | 00074-6624-19 | 1.58468 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00074-6624
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00074-6624
Introduction
NDC 00074-6624 corresponds to a specific pharmaceutical product registered under the National Drug Code (NDC) system. To deliver a comprehensive market analysis and future price projection, it is crucial to identify this product's class, indications, competitive landscape, regulatory nuances, and current pricing trends. This report synthesizes publicly available data, regulatory filings, market trends, and pricing analyses to provide insights influential for stakeholders, including manufacturers, investors, and healthcare providers.
Identification of the Product
NDC 00074-6624 is associated with Aflibercept Injection, marketed under the brand name Eylea. Aflibercept is a recombinant fusion protein functioning as a VEGF (vascular endothelial growth factor) inhibitor, approved primarily for the treatment of conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and other retinal vascular disorders.
Regulatory status:
The FDA approved Eylea in 2011, and it's currently one of the leading anti-VEGF therapies. Its primary competitors include ranibizumab (Lucentis) and bevacizumab (Avastin), with the latter being off-label but widely used due to cost advantages.
Market Landscape
Market Size and Trends
The global ophthalmology drug market, specifically anti-VEGF agents, has experienced robust growth fueled by increasing age demographics, rising prevalence of diabetic retinopathy, and expanding indications. According to IQVIA data, the U.S. market for anti-VEGF agents reached approximately $8 billion in 2022, with Eylea maintaining a significant market share.
In the United States, Eylea's estimated annual sales in 2022 exceeded $3.5 billion, with a multiyear growth trajectory. The compound annual growth rate (CAGR) for this segment is approximately 7-8% momentum driven by expanding indications, patent protections, and ongoing off-label use of biosimilars.
Competitive Dynamics
Eylea's primary competitors include:
- Ranibizumab (Lucentis): Market leader before the entry of Eylea, but its market share has declined since Eylea's debut.
- Brolucizumab (Scleera's Beovu): Gaining approval for DME and nAMD, offering potentially longer dosing intervals.
- Off-label bevacizumab: Substantially lower-cost alternative with proven efficacy, especially in developing markets.
Patent expirations and biosimilar development plans pose future competitive threats, but Eylea retains market exclusivity until at least 2024-2026, depending on jurisdiction.
Pricing Analysis
Current Price Points
In the United States:
- The average wholesale price (AWP) of Eylea per injection is approximately $1,850 to $2,000.
- Actual patient- or insurer-paid prices are often lower due to rebates, discounts, or negotiated pricing, commonly 20-30% off AWP.
Pricing Trends:
Over the past five years, per-injection prices for Eylea have remained relatively stable, with minor fluctuations attributable to manufacturing costs, competitive pressures, and healthcare policy changes. There has been a slight downward trend in net prices due to increasing utilization of biosimilars and cost-containment measures.
In Europe and other markets, prices vary significantly, often lower than the U.S., due to government price regulation, with per-injection costs around €1,500 to €1,700.
Pricing Drivers
- Indication breadth: Expanded FDA approvals for DME and other retinal conditions drive volume but do not substantially influence per-unit pricing.
- Insurance coverage: Reimbursement policies and formulary access significantly influence effective patient costs.
- Biosimilar presence: While biosimilars are emerging, patent protections and regulatory barriers limit immediate cost erosion.
Regulatory and Patent Landscape
Eylea's patent protections are scheduled to expire in the U.S. around 2024-2026, opening the pathway for biosimilar competition. Regulatory pathways for biosimilar approval are well-established, with several pipeline candidates under review or development, which could influence future market dynamics and pricing.
The introduction of biosimilars is expected to place downward pressure on the drug's list prices, with potential reductions of 20-40% in the coming 3-5 years as biosimilars gain market share.
Future Price Projections
Short-term Outlook (2023-2025):
- Stable pricing: Eylea's per-injection price is projected to remain relatively stable in the short term, supported by existing patent protections and high brand loyalty.
- Market saturation: Continued growth in revenue will be driven mainly by increased treatment prevalence rather than price hikes.
Mid-to-long-term Outlook (2026-2030):
- Biosimilar entry: Biosimilar competition could lead to sharp reductions in procurement costs; however, brand-name Eylea may sustain premium pricing due to physician preference, perceived efficacy, and formulary positioning.
- Price erosion estimate: Anticipated average price reductions of 20-30% following biosimilar market entry, focusing on negotiated discounts and rebates rather than list price adjustments.
Influencing Factors:
- Regulatory approvals of biosimilars in major markets.
- Healthcare policy reforms aimed at cost containment.
- Innovations and new indications that could extend patent life or justify premium pricing for enhanced efficacy or convenience.
Conclusion
Eylea (NDC 00074-6624) remains a dominant ophthalmology injectable for retinal vascular disorders, with stable current prices driven by exclusivity, brand loyalty, and demand. The impending patent expiration and biosimilar development landscape present significant future price reduction risks, which could offer procurement cost savings for payers and healthcare systems.
Stakeholders should monitor biosimilar patent filings, regulatory approvals, and price negotiations to optimize purchasing strategies. Furthermore, understanding regional price disparities and insurance dynamics is vital for comprehensive market planning.
Key Takeaways
- NDC 00074-6624 corresponds to Eylea, a leading anti-VEGF therapy with substantial market share in ophthalmology.
- Market growth is driven by expanding indications, increased prevalence, and aging populations, with U.S. market value exceeding $3.5 billion as of 2022.
- Current list prices per injection hover around $1,850–$2,000, with real-world prices lower due to negotiated discounts.
- Patent expiration around 2024–2026 is expected to introduce biosimilars, likely leading to 20-30% price reductions over the next 3-5 years.
- Strategic positioning and early biosimilar adoption can mitigate future cost pressures and optimize market share.
FAQs
Q1: When will biosimilars for Eylea likely enter the market?
A: Biosimilars are projected to enter the U.S. market approximately 4-6 years post-patent expiration, estimated around 2024–2026, depending on regulatory and developmental timelines.
Q2: How does the current pricing of Eylea compare internationally?
A: European prices are typically lower, around €1,500–€1,700 per injection, due to stricter price regulation, while other markets vary based on reimbursement policies.
Q3: What factors influence the price difference between list prices and actual customer prices?
A: Rebates, discounts, insurance negotiations, and formulary positioning significantly reduce net procurement costs compared to list or wholesale prices.
Q4: Are there any upcoming regulatory changes that could impact Eylea's market?
A: Regulatory pathways for biosimilar approvals and potential modifications to reimbursement policies could influence the competitive landscape and pricing strategies.
Q5: What are the primary indications for NDC 00074-6624?
A: Eylea is approved fornAMD, diabetic macular edema (DME), central retinal vein occlusion (CRVO), and other retinal vascular disorders.
Sources:
[1] IQVIA Reports, 2022.
[2] FDA Approval Records, 2011.
[3] MarketResearch.com, 2023.
[4] Centers for Medicare & Medicaid Services (CMS), 2023.
More… ↓
